Estimating Preventable Fractions of Disease Caused by a Specified Biological Mechanism: PAHs in Smoking Lung Cancers as an Example

Epidemiology textbooks often interpret population attributable fractions based on 2 x 2 tables or logistic regression models of exposure-response associations as preventable fractions, i.e., as fractions of illnesses in a population that would be prevented if exposure were removed. In general, this causal interpretation is not correct, since statistical association need not indicate causation; moreover, it does not identify how much risk would be prevented by removing specific constituents of complex exposures. This article introduces and illustrates an approach to calculating useful bounds on preventable fractions, having valid causal interpretations, from the types of partial but useful molecular epidemiological and biological information often available in practice. The method applies probabilistic risk assessment concepts from systems reliability analysis, together with bounding constraints for the relationship between event probabilities and causation (such as that the probability that exposure X causes response Y cannot exceed the probability that exposure X precedes response Y, or the probability that both X and Y occur) to bound the contribution to causation from specific causal pathways. We illustrate the approach by estimating an upper bound on the contribution to lung cancer risk made by a specific, much-discussed causal pathway that links smoking to a polycyclic aromatic hydrocarbon (PAH) (specifically, benzo(a)pyrene diol epoxide-DNA) adducts at hot spot codons at p53 in lung cells. The result is a surprisingly small preventable fraction (of perhaps 7% or less) for this pathway, suggesting that it will be important to consider other mechanisms and non-PAH constituents of tobacco smoke in designing less risky tobacco-based products.

[1]  John K Leighton,et al.  Application of Emerging Technologies in Toxicology and Safety Assessment: Regulatory Perspectives , 2005, International journal of toxicology.

[2]  C. Harris,et al.  TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. , 2004, IARC scientific publications.

[3]  João F. Martins,et al.  Neural Networks and Logical Reasoning Systems: A Translation Table , 2001, Int. J. Neural Syst..

[4]  Ronen I. Brafman,et al.  A simplifier for propositional formulas with many binary clauses , 2001, IEEE Transactions on Systems, Man, and Cybernetics, Part B (Cybernetics).

[5]  Jr. Louis A. Cox,et al.  A New Measure of Attributable Risk for Public Health Applications , 1985 .

[6]  N. Tretyakova,et al.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.

[7]  H. Bartsch,et al.  CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. , 2002, Carcinogenesis.

[8]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[9]  P. Hainaut,et al.  On the origin of G --> T transversions in lung cancer. , 2003, Mutation research.

[10]  Erika Gyorffy,et al.  DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay. , 2004, Carcinogenesis.

[11]  R. Santella,et al.  Removal of benzo(a)pyrene diol epoxide (BPDE)‐DNA adducts as a measure of DNA repair capacity in lymphoblastoid cell lines from sisters discordant for breast cancer , 2002, Environmental and molecular mutagenesis.

[12]  W. El-Deiry,et al.  Clinical implications of p53 mutations in lung cancer. , 2003, Methods in molecular medicine.

[13]  Marilyn J Aardema,et al.  Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. , 2002, Mutation research.

[14]  M. Spitz,et al.  In vitro BPDE‐induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck , 2001, International journal of cancer.

[15]  S D Stellman,et al.  Smoking and lung cancer risk in American and Japanese men: an international case-control study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  Mark S. Clements,et al.  Multistage Carcinogenesis and Lung Cancer Mortality in Three Cohorts , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  S. Glantz,et al.  The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest , 2005, The Lancet.

[18]  M. Höfler,et al.  Causal inference based on counterfactuals , 2005, BMC medical research methodology.

[19]  U. Heinrich,et al.  Relative significance of different hydrocarbons for the carcinogenic potency of emissions from various incomplete combustion processes. , 1990, IARC scientific publications.

[20]  E. Bowman,et al.  Smoking increases carcinogenic polycyclic aromatic hydrocarbons in human lung tissue. , 2001, Cancer research.

[21]  Sander Greenland,et al.  An overview of relations among causal modelling methods. , 2002, International journal of epidemiology.

[22]  J. Wreathall,et al.  Assessing risk: the role of probabilistic risk assessment (PRA) in patient safety improvement , 2004, Quality and Safety in Health Care.

[23]  S. Rodin,et al.  On the excess of G --> T transversions in the p53 gene in lung cancer cell lines. Reply to Pfeifer and Hainaut. , 2004, Mutation research.

[24]  S. Rodin,et al.  On the origin of p53 G:C --> T:A transversions in lung cancers. , 2002, Mutation research.

[25]  S. Greenland,et al.  Causation and causal inference in epidemiology. , 2005, American journal of public health.

[26]  P. Dolara,et al.  Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. , 1998, Chemico-biological interactions.

[27]  M. Spitz,et al.  Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. , 2001, Cancer research.

[28]  Yung-Ruei Chang,et al.  Computing system failure frequencies and reliability importance measures using OBDD , 2004, IEEE Transactions on Computers.

[29]  I. Cascorbi,et al.  High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. , 2004, Cancer letters.

[30]  M. Schulze,et al.  Estimating the proportion of disease due to classes of sufficient causes. , 2006, American journal of epidemiology.

[31]  J M Robins,et al.  Conceptual problems in the definition and interpretation of attributable fractions. , 1988, American journal of epidemiology.

[32]  G. Glazko,et al.  Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection. , 2004, Biochimica et biophysica acta.

[33]  P. Andersen,et al.  Multivariate competing risks. , 1999, Statistics in medicine.

[34]  R. Millikan,et al.  Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. , 2002, Cancer research.